Their product, ocustatin, targets patients in the intermediate stage of the disease, offering a much-needed solution to prevent progression to late-stage vision loss. Developed at Harvard University and backed by a successful proof-of-concept clinical trial, ocustatin has demonstrated a 75% reduction in the advancement towards late-stage blindness. Drusolv's founder and CEO, John Edwards, brings extensive experience in the field of AMD, making the company well-positioned to address this critical medical need.